Acute lymphoblastic leukemia in children: Treatment planning via minimal residual disease assessment;Akute lymphoblastische Leukämie bei Kindern: Therapiesteuerung durch den Nachweis von MRD (minimal residual disease)

Deutsches Arzteblatt International

Volumn 109, Issue 40, 2012, Pages 652-658

  Bartram, Claus R ^a   Schrauder, André ^b   Köhler, Rolf ^a   Schrappe, Martin ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; B CELL LEUKEMIA; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CLINICAL ASSESSMENT; EVENT FREE SURVIVAL; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PRE B LYMPHOCYTE; PREDICTION; REVIEW; T CELL LEUKEMIA; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 84899772150     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2012.0652     Document Type: Review

References (29)

1. Riehm H, Gadner H, Henze G, et al.: Results and significance of six randomized trials in four consecutive ALL BFM trials. Haematol Blood Transf 1990; 33: 439-50.
2. Conter V, Aricò M, Basso G, et al.: Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 255-64.
3. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-78.
4. Moghrabi A, Levy DE, Asselin B, et al.: Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896-904.
5. Aricò M, Valsecchi MG, Rizzari C, et al.: Long-term results of the AIEOPALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol 2008; 26: 283-9.
6. Möricke A, Zimmermann M, Reiter A, et al.: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010; 24: 265-84.
7. Reiter A, Schrappe M, Ludwig WD, et al.: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-33.
8. Gaynon PS, Desai AA, Bostrom BC, et al.: Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997; 80: 1717-26.
9. Dördelmann M, Reiter A, Borkhardt A, et al.: Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-17.
10. Brüggemann M, Schrauder A, Raff T, et al.: European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); Internation al Berlin-Frankfurt-Münster Study Group (I-BFM-SG). Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24: 521-35.
11. Bassing CH, Swat W, Alt FW: The mechanism and regulation of chromosomal V(D)J recombination. Cell 2002; 109 (Suppl): 45-55.
12. Hansen-Hagge TE, Yokota S, Bartram CR: Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplifica tion of rearranged T-cell receptor delta chain sequences. Blood 1989; 74: 1762-7.
13. Yamada M, Hudson S, Tournay O, et al.: Detection of minimal dis ease in hematopoietic malignancies of the B-cell lineage by using third-complementarity- determining region (CDR-III)-specific probes. Proc Natl Acad Sci (U S A) 1989; 86: 5123-7.
14. van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al.: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-8.
15. Cavé H, van der Werfften Bosch J, Suciu S, et al.: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 1998; 339: 591-8.
16. Flohr T, Schrauder A, Cazzaniga G, et al.: International BFM Study Group (I-BFM-SG). Minimal residual disease-directed risk stratifica tion using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-82.
17. Pongers-Willemse MJ, Seriu T, Stolz F, et al.: Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 110-8.
18. van der Velden VH, Cazzaniga G, Schrauder A, et al.: European Study Group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guide lines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604-11.
19. Conter V, Bartram CR, Valsecchi MG, et al.: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 22: 3206-14.
20. Möricke A, Reiter A, Zimmermann M, et al.: German-Austrian-Swiss ALL-BFM Study Group. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-89.
21. Schrappe M, Valsecchi MG, Bartram CR, et al.: Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118: 2077-84.
22. Borowitz MJ, Devidas M, Hunger SP, et al.: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Childrens' Oncology Group study. Blood 2008; 111: 5477-85.
23. Stow P, Key L, Chen X, et al.: Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010, 115: 4657-63.
24. Bassan R, Spinelli O, Oldani E, et al.: Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113: 4153-62.
25. Gökbuget N, Kneba M, Raff T, et al.: Adults with acute lymphoblastic leukemia and molecular failure display a poor diagnosis and are candidates for stem cell transplantation and targeted therapies. Blood, 2012 (in press).
26. Moreton P, Kennedy B, Lucas G, et al.: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971-9.
27. Buccisano F, Maurillo L, Del Principe MI, et al.: Prognostic and therapeutic implications of minimal residual disease in acute myeloid leukemia. Blood 2012; 119: 332-41.
28. Helhlmann, R, Hochhaus A, Baccarani M: Chronic myeloid leukaemia. Lancet 2007; 370: 342-50.
29. Riethdorf S, Wikman H, Pantel K: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008; 123: 1991-2006.